Paris, France and Camberley, UK – 20 April 2022 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it will report its audited financial results for the year ended 31 December 2021 on Thursday, 28 April 2022. http://novacyt.com/wp-content/uploads/2022/04/Notice-of-FY21-Results-.pdf
Visit PageAuthor: mandycowling
Avis sur les résultats de l’exercice 2021 et présentation aux investisseurs
Paris, France et Camberley, Royaume-Uni – 20 avril 2022 – Novacyt (EURONEXT GROWTH : ALNOV ; AIM : NCYT), spécialiste international du diagnostic clinique, annonce qu’elle présentera ses résultats financiers audités pour l’exercice clos le 31 décembre 2021 le jeudi 28 avril 2022. http://novacyt.com/wp-content/uploads/2022/04/Novacyt-Avis-sur-les-resultats-de-lexercice-2021-et-presentation-aux-investisseurs-.pdf
Visit PageApproval of second direct-to-PCR COVID-19 test in the UK under CTDA legislation
Paris, France and Camberley, UK – 12 April 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that the Company’s PROmate® COVID-19 1G (q32) Real-Time PCR test has been approved in the UK under the UK Health Security Agency’s Medical Devices (Coronavirus Test Device Approvals) (Amendment) Regulations 2021 (“CTDA”).
Visit Page